FDA Sets Limits on Darvon and Darvocet but Doesn’t Recommend Market Withdrawal

Despite recommendations from two of its advisory committees for a phased withdrawal of propoxyphene-containing products, the Food and Drug Administration won’t be taking them off the market.  Instead they’ll require a black box warning on the label and a medication guide for patients letting them know of the serious risks of death from effects on the heart or overdose.

Best known by brand names Darvon® and Darvocet®, the pain medicines have a high risk for fatal overdose when not used as prescribed.  Opiates, they are prescribed for mild to moderate pain.  However, the FDA says that benefits of the medicines when taken at recommended doses outweigh risks at this time.

The FDA is also requiring that the manufacturer conduct a safety study to determine the risks of propoxyphene on the heart when taken above the recommended dose.

The agency also denied a  2006 citizen petition to remove Darvon and other propoxyphene-containing drugs from the market.  The advocacy organization Public Citizen had petitioned the FDA to ban propoxyphene drugs because of potential heart problems, risks of abuse, fatal accidental overdoses, and relatively weak painkilling effectiveness.

On June 25, 2009, the European Medicines Agency (EMEA) recommended that member states gradually withdraw propoxyphene products from their markets.  The EMEA recommendation was based on the number of suicides and accidental fatal overdoses of the drug and on their conclusion that there is no evidence that propoxyphene is more effective than other available pain medicines.   The medicine was withdrawn from the United Kingdom market in 2005 for similar reasons.

More information from the FDA about the decision and about proproxyphene.

Bookmark and Share

This news article was originally posted on August 7th, 2009 and was accurate at the time of publication. Since then, information may have changed or links may now be outdated. Please call our Answer Line 1-877-427-2111 for the latest information, or talk to your doctor before making any medical decisions.

Posted by Kate Murphy on August 7th, 2009
Tags: Darvon, FDA, propoxyphene

Leave a Comment Comments RSS

Your comments are welcome. However, specific medical advice will not be provided, and we urge you to consult with a qualified physician for diagnosis and for answers to your personal questions. C3 is not responsible for the medical accuracy of any comments left by persons other than C3 staff members. C3 staff members monitor comments and may respond publicly where appropriate.

Please note that we automatically publish the name that you enter next to your post. Also note that our pages are automatically indexed by Google and other search engines, and your name may therefore appear in search results on those sites. So if you wish to remain anonymous please use a different name or enter 'Anon' as the name.

We regret that we are unable to privately answer questions left as comments. So please do not include your phone number, email or mailing address in the body of your comment. For the best personal and direct response to your colorectal cancer treatment questions, please call our Answer Line at 1-877-4CRC-111 (1-877-427-2111).

Search C3

Register to receive our free e-newsletter

Get monthly updates on colorectal cancer treatment options, research news and advocacy opportunities. We promise to not bombard you with email - just enough to keep you informed on how to fight colorectal cancer.

First Name

Last Name

Email

Donate

Support C3 and the Lisa Fund for Research

Donate to C3

Donate to The Lisa Fund

Learn more about the Lisa Fund

Sign Our Petition

Guarantee access to colorectal cancer screening for all Americans who need it.

Get Involved

Subscribe to the C3 website

Get C3 news & updates

Get the latest articles in your email inbox or news reader as soon as they are published.

Subscribe